Atossa Therapeutics ATOS Stock
Atossa Therapeutics Price Chart
Atossa Therapeutics ATOS Financial and Trading Overview
| Atossa Therapeutics stock price | 0.6 USD |
| Previous Close | 0.9 USD |
| Open | 0.91 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 2200 |
| Day's Range | 0.85 - 0.92 USD |
| 52 Week Range | 0.5 - 1.24 USD |
| Volume | 553.26K USD |
| Avg. Volume | 477.03K USD |
| Market Cap | 113.81M USD |
| Beta (5Y Monthly) | 1.169366 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.63 USD |
ATOS Valuation Measures
| Enterprise Value | 10.68M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.5952 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.0098877 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.355 |
Trading Information
Atossa Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.169366 |
| 52-Week Change | -13.46% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.24 USD |
| 52 Week Low | 0.5 USD |
| 50-Day Moving Average | 0.77 USD |
| 200-Day Moving Average | 0.77 USD |
ATOS Share Statistics
| Avg. Volume (3 month) | 477.03K USD |
| Avg. Daily Volume (10-Days) | 551.42K USD |
| Shares Outstanding | 126.62M |
| Float | 118.83M |
| Short Ratio | 10.45 |
| % Held by Insiders | 0.041% |
| % Held by Institutions | 20.66% |
| Shares Short | 7.52M |
| Short % of Float | 5.94% |
| Short % of Shares Outstanding | 5.94% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:12 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -14.80% |
| Return on Equity (ttm) | -22.91% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -30033000 USD |
| Net Income Avi to Common (ttm) | -28455000 USD |
| Diluted EPS (ttm) | -0.21 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 103.87M USD |
| Total Cash Per Share (mrq) | 0.82 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 37.659 |
| Book Value Per Share (mrq) | 0.89 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -22904000 USD |
| Levered Free Cash Flow (ttm) | -13243250 USD |
Profile of Atossa Therapeutics
| Country | United States |
| State | WA |
| City | Seattle |
| Address | 107 Spring Street |
| ZIP | 98104 |
| Phone | 206 588 0256 |
| Website | https://atossatherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 11 |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Q&A For Atossa Therapeutics Stock
What is a current ATOS stock price?
Atossa Therapeutics ATOS stock price today per share is 0.6 USD.
How to purchase Atossa Therapeutics stock?
You can buy ATOS shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Atossa Therapeutics?
The stock symbol or ticker of Atossa Therapeutics is ATOS.
Which industry does the Atossa Therapeutics company belong to?
The Atossa Therapeutics industry is Biotechnology.
How many shares does Atossa Therapeutics have in circulation?
The max supply of Atossa Therapeutics shares is 129.17M.
What is Atossa Therapeutics Price to Earnings Ratio (PE Ratio)?
Atossa Therapeutics PE Ratio is now.
What was Atossa Therapeutics earnings per share over the trailing 12 months (TTM)?
Atossa Therapeutics EPS is -0.2 USD over the trailing 12 months.
Which sector does the Atossa Therapeutics company belong to?
The Atossa Therapeutics sector is Healthcare.
Atossa Therapeutics ATOS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
| NASDAQ Capital Market Composite RCMP | 92.16 USD — |
-4.45
|
— — | 89.57 USD — | 93.85 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19079.55 USD — |
-5.82
|
— — | 19064.73 USD — | 19740.96 USD — | — - | — — |
- {{ link.label }} {{link}}